Beam Therapeutics Inc.
BEAM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.29 | 0.36 | 4.57 |
| FCF Yield | -17.45% | -8.71% | -0.96% | -2.21% |
| EV / EBITDA | -5.00 | -11.74 | -8.28 | -10.94 |
| Quality | ||||
| ROIC | -44.44% | -14.08% | -30.34% | -28.44% |
| Gross Margin | 65.48% | -15.80% | 62.94% | 68.29% |
| Cash Conversion Ratio | 0.92 | 1.13 | -0.08 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.40% | 93.86% | 1,264.11% | 1,322.79% |
| Free Cash Flow Growth | -94.72% | -592.28% | 76.63% | -0.88% |
| Safety | ||||
| Net Debt / EBITDA | 0.31 | 1.68 | 0.17 | 2.10 |
| Interest Coverage | 0.00 | 0.00 | -22.13 | -43,607.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.03 |
| Cash Conversion Cycle | -64.44 | -1.35 | -145.97 | -11,537.58 |